|
Market Closed -
Nasdaq
23:00:00 12/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 150.43 USD | -0.49% |
|
+4.01% | +22.56% |
| 10-12 | Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says | MT |
| 10-12 | BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- GILD Stock
- Consensus Gilead Sciences, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
